Glimepiride & Metformin Hydrochloride Prolonged Release GLIMITERIS M1 Glimepiride and Metformin Hydrochloride Prolonged Release are oral antidiabetic medications often used in combination to manage type 2 diabetes mellitus. Each of these drugs belongs to a different class of diabetes medications and works in a unique way: Glimepiride: Class: Sulfonylurea. Mechanism of Action: Glimepiride primarily works by stimulating insulin release from the beta cells in the pancreas. This increase in insulin helps to lower blood sugar levels. Usage: It's typically used for improving blood sugar control in adults with type 2 diabetes. Considerations: The main side effect of sulfonylureas, including glimepiride, is the risk of hypoglycemia (low blood sugar), particularly if meals are missed or delayed, or if the dose is too high. Metformin Hydrochloride Prolonged Release: Class: Biguanide. Mechanism of Action: Metformin works by decreasing glucose production in the liver, decreasing intestinal absorption of sugar, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Usage: It's commonly used as a first-line treatment for type 2 diabetes and is particularly effective in overweight and obese patients. Considerations: Metformin is generally well-tolerated but can cause gastrointestinal side effects like diarrhea, nausea, and abdominal pain. The prolonged-release form is designed to reduce these side effects. Rarely, metformin can lead to a serious condition called lactic acidosis, more likely in patients with kidney problems. The combination of these two medications can effectively control blood sugar levels in people with type 2 diabetes, particularly when one medication alone is not sufficient. The combination offers the benefits of both medications while potentially reducing the risk of side effects associated with higher doses of either drug alone. Patients taking this combination should have regular follow-up appointments with their healthcare provider to monitor their blood sugar levels and adjust the treatment accordingly. It's also important to maintain a balanced diet and regular exercise as part of diabetes management. Steris Healthcare Pvt. Ltd. is a Leading Pharmaceutical Company in India. Established in the year of May 2018. We have 750+ Products & 16+ Super Specialty Segments. Every week we have a new product in our portfolio. In Last 5 years we are dealing in Chronic Therapy and in 5 years we grow by 200% Annually, because we deal in high quality medicine. Steris medicine manufactures at WHO-GMP Approved Plants & We have Legal manufacturing contracts with all leading manufacturers of India. Today we have 1000+ Business Franchise Partners in PAN India. Steris's medicine supply in India's Top or Reputed Hospitals, Pharmacy, Government use or Railway use. Grow with a similar pace with the STERIS. Be first to launch like us. For further information please contact: info@sterispharma.com order now:https://www.sterisonline.com/product/glimiteris-m1-134333